Marksans Pharma Ltd (MARKSANS) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Marksans Pharma enters the new fiscal year following a milestone FY26 where it surpassed Rs. 3,000 crore in total income and significantly expanded its global footprint. Investors are looking to see how the company navigates Q1's seasonal revenue dip and inflationary cost pressures while balancing its ambitious 15-20% revenue growth target for FY27.

Marksans Pharma Ltd Q1 Results Date and Time

The board meeting is scheduled for August 12, 2026, to consider the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026.

The earnings conference call is scheduled for August 13, 2026, at 4:30 PM IST, with Mr. Mark Saldanha (CMD) and Mr. Jitendra Sharma (CFO) as the management speakers.

What to expect from Marksans Pharma Ltd's Q1 FY27 results

Marksans Pharma is expected to show YoY revenue growth on the low Q1FY26 base of Rs. 620 Cr, though a sequential decline from the record Q4FY26 revenue of Rs. 891 Cr is anticipated due to seasonal dispatch scheduling. While management has guided for 15-20% revenue growth in FY27, they have explicitly flagged inflationary headwinds impacting the current quarter, which may weigh on EBITDA margins. Margins are expected to compress from the Q4 peak of 22.8% due to this cost pressure and lower operating leverage typical of the seasonally weakest first quarter. The company's progress toward its 20-21% EBITDA margin guidance for FY27 will be a key focus, as will the integration of recent European acquisitions like QliniQ B.V. and ABCnow GmbH.

Key Things To Watch

Performance vs Guidance Tracking: Monitoring progress against management's stated FY27 and long-term targets.

• Group revenue growth — 15% to 20% target for FY27 — Status: Tracking
• EBITDA margin — 20% to 21% target for FY27 — Status: Tracking
• Working capital days — 120-130 days normalization target — Status: Tracking

Operating metric trajectory: Key indicators of demand health and operational efficiency.

• US order book — $225-230 million as of H1/Q3 FY26 — Update on conversion timing
• US product launches — ~50 new launches planned for FY27 — Status of pipeline
• UK revenue — Record Rs. 308 Cr in Q4FY26 — Sustainability of recovery

Strategic execution and M&A: Updates on recent inorganic and organic expansion efforts.

• QliniQ B.V. integration — 2-week contribution in Q1 — Revenue synergy expectations
• ABCnow GmbH — Closed July 31, 2026 — Integration timeline and outlook
• Canada entry — 14 products filed — Status of initial revenue contributions

Risks and headwinds to monitor: External factors impacting near-term profitability.

• Inflationary headwinds — Expected impact on Q1 FY27 margins per management
• Pricing pressure in UK — 60% OTC/40% Rx mix volatility — Monitoring price erosion
• R&D investment — Elevated at 3% of revenue — Pay-off timeline for late 2027/early 2028